Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina
Authors:
- Diane UschnerDUDiane Uschner
- Michele SantacatterinaMSMichele Santacatterina
- Mihili GunaratneMGMihili Gunaratne
Preprint
Abstract
Importance Real-world data are needed to assess incidence and factors associated with breakthrough SARS-CoV-2 infections following vaccination. Objective Estimate incidence of breakthrough infections and assess associations with risk factors using self-reported data from a large NC population sample. Design Prospective observational cohort study utilizing daily online survey data to capture information about COVID-19 symptoms, testing, and vaccination status. Setting Six health care systems in North Carolina with data collected between January 15, 2021 and September 24, 2021. Participants Adult study participants who reported full vaccination with a COVID-19 mRNA or J&J non-replicating viral vector vaccine (n =16,020). Exposures Potential community exposure to SARS-CoV-2. Main Outcome and Measures Self-reported breakthrough infection. Results SARS-CoV-2 infection after vaccination was self-reported in 1.9% of participants, with an incidence rate of 7.3 per 100,000 person-years. Younger age (45-64 vs. 18-44: HR (95% CI) = 0.65 (0.51 - 0.82); 65+ vs. 18-44: HR (95% CI) = 0.59 (0.39 - 0.90)), and vaccination with J&J Ad26.COV2.S were associated with a higher risk of breakthrough infection compared to vaccination with Pfizer BNT162b2 (Ad26.COV2.S vs. BNT162b2: HR (95% CI) = 2.23 (1.40 - 3.56)), while participants vaccinated with mRNA-1273 (mRNA-1273 vs. BNT162b2: HR (95% CI) = 0.69 (0.50 – 0.96) and those residing in urban counties experienced a lower rate of SARS-CoV-2 breakthrough infection compared with those from suburban (HR (95% CI) = 1.39 (1.01 – 1.90) or rural (HR (95% CI) = 1.57 (1.16 – 2.11) counties. There was no significant association between breakthrough infection and participant sex, race, healthcare worker status, prior COVID-19 infection, routine mask use, or overall vaccination rate in the county of residence. Conclusions and Relevance This NC community-based observational study showed that the proportion of the cohort who self-report breakthrough SARS-CoV-2 infections was 7.3 events per 100,000 person-years. Younger adults, those vaccinated with J&J Ad26.COV2.S, and those residing in suburban or rural counties were at higher risk of breakthrough infections and should be targeted for additional risk mitigation strategies to decrease community transmission. Trial Registration The COVID-19 Community Research Partnership is listed in clinicaltrials.gov (NCT04342884). Question What are the characteristics of those with breakthrough infections after SARS-CoV-2 vaccination in North Carolinaã Findings In this NC-based observational study of 16,020 participants, 1.9% self-reported a positive SARS-CoV-2 viral test at least 2 weeks following full vaccination, reflecting an event rate of 7.3 infections per 100,000 person years. Rates were higher among younger participants, participants from more rural areas in North Carolina, and those vaccinated with J&J Ad26.COV2.S. Meaning Our results show a relatively low rate of COVID-19 infection following full vaccination. Younger adults and those vaccinated with J&J Ad26.COV2.S should be targeted for additional risk mitigation strategies.Keywords
All Related Versions
- Published version: Vaccines, 10 (11), 1922.
This publication has 9 references indexed in Scilit:
- Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variantsScience, 2021
- Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort studyThe Lancet Regional Health - Americas, 2021
- Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After VaccinationInternational Journal of Infectious Diseases, 2021
- Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance — Eight U.S. Locations, December 2020–August 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Effect of Vaccination on Household Transmission of SARS-CoV-2 in EnglandNew England Journal of Medicine, 2021
- Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 VaccinesNew England Journal of Medicine, 2021
- Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19New England Journal of Medicine, 2021
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020